Source comparison
SS-31 Dosage Protocol Comparison
The following table compares dosing protocols from major published research categories, highlighting the body weight calculations, administration routes, and timing considerations that determine effective mitochondrial targeting. Cardiac Ischemia-Reperfusion 0
This comparison does not assign a generated winner or score.
- The following table compares dosing protocols from major published research categories, highlighting the body weight calculations, administration routes, and timing considerations that determine effective mitochondrial targeting.
- Cardiac Ischemia-Reperfusion
- 0.3–0.5
- Subcutaneous or IV bolus
- 30–60 min before ischemia
- High cardiac mitochondrial density (35% cell volume) demands higher dosing for threshold effects
- Most robust preclinical data; dose translates poorly to clinical use due to pharmacokinetic scaling
- Chronic Heart Failure (Clinical)
- 0.05–0.06
- Subcutaneous daily
- Continuous maintenance
- Chronic dosing prioritizes safety over peak effect; lower per-dose amounts accumulate over weeks
- EMBRACE trial dosing—safe but marginal efficacy; may represent undertitration
- Renal Ischemia-Reperfusion
- 0.25
- Intravenous bolus
- Immediately pre-ischemia
- IV route ensures peak plasma during injury; kidneys clear peptides rapidly, requiring timing precision
- Dose reflects IV pharmacokinetics, not tissue requirements; subcutaneous equivalent would be higher
- Traumatic Brain Injury
- 0.05–0.15
- Intraperitoneal or IV
- Within 1 hour post-injury, repeated at 6h
- Lower neuronal mitochondrial density; BBB penetration limits; repeat dosing sustains levels
- Conservative dosing minimizes peripheral effects while achieving CNS threshold
- Metabolic Dysfunction / NAFLD
- 0.1–0.25
- Chronic (4–12 weeks)
- Hepatic mitochondrial volume ~20%; chronic protocols allow lower per-dose amounts
- Moderate dosing balances efficacy and long-term safety; dose-response plateaus above 0.25mg/kg
- Skeletal Muscle Atrophy
- 0.2–0.3
- Preventive (before disuse) or therapeutic (during recovery)
- Skeletal muscle mitochondrial content variable (8–12%); dosing targets type I fibers preferentially
- Emerging research area; optimal dosing unclear; current protocols adapted from cardiac studies